Literature DB >> 8980391

Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells.

L Orlandi1, N Zaffaroni, A Bearzatto, R Silvestrini.   

Abstract

We previously reported that combined treatment with melphalan and mild hyperthermia (1 h at 42 degrees C) caused a synergistic cytotoxic effect in JR8 melanoma cells, paralleled by a stabilisation of a melphalan-induced G2-phase cell block. In this study, we investigated the effect of melphalan and hyperthermia on proteins that regulate G2-M transition. Neither hyperthermia nor melphalan at a concentration of 2.5 micrograms ml-1, which had no antiproliferative effect at 37 degrees C, interfered with cyclin B1 expression or p34cdc2 kinase activity. At a concentration of 8.5 micrograms ml-1, which reduced cell growth by 50% at 37 degrees C, melphalan inhibited p34cdc2 kinase activity as a consequence of an increased tyrosine phosphorylation of the protein. A similar inhibitory effect on p34cdc2 kinase was obtained when the lowest melphalan concentration (2.5 micrograms ml-1) was used under hyperthermic conditions. Our results indicate that thermal enhancement of melphalan cytotoxicity could be mediated at least in part by an inhibition of p34cdc2 kinase activity, which prevents cell progression into mitosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980391      PMCID: PMC2074806          DOI: 10.1038/bjc.1996.654

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

Review 1.  Universal control mechanism regulating onset of M-phase.

Authors:  P Nurse
Journal:  Nature       Date:  1990-04-05       Impact factor: 49.962

Review 2.  Driving the cell cycle: M phase kinase, its partners, and substrates.

Authors:  B Lewin
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  The effect of hyperthermia on the uptake and cytotoxicity of melphalan in Chinese hamster ovary cells.

Authors:  D A Bates; W J Mackillop
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-01       Impact factor: 7.038

Review 4.  G2 block induced by DNA crosslinking agents and its possible consequences.

Authors:  J Konopa
Journal:  Biochem Pharmacol       Date:  1988-06-15       Impact factor: 5.858

5.  Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities.

Authors:  M Santinami; F Belli; N Cascinelli; D Rovini; M Vaglini
Journal:  J Surg Oncol       Date:  1989-11       Impact factor: 3.454

6.  Effects of hyperthermia on repair of radiation-induced DNA strand breaks.

Authors:  M D Mills; R E Meyn
Journal:  Radiat Res       Date:  1981-08       Impact factor: 2.841

7.  Cyclin activation of p34cdc2.

Authors:  M J Solomon; M Glotzer; T H Lee; M Philippe; M W Kirschner
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

8.  The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma.

Authors:  F Ghussen; I Krüger; W Groth; H Stützer
Journal:  Cancer       Date:  1988-02-15       Impact factor: 6.860

9.  Effect of melphalan and hyperthermia on cell cycle progression and cyclin B1 expression in human melanoma cells.

Authors:  L Orlandi; N Zaffaroni; A Bearzatto; A Costa; R Supino; M Vaglini; R Silvestrini
Journal:  Cell Prolif       Date:  1995-11       Impact factor: 6.831

10.  Heterogeneous radiation and heat sensitivity in vitro of human melanoma xenograft lines established from different lesions in the same patient. Comparisons with the radiation and heat sensitivity of cells isolated from the donor patient's surgical specimens.

Authors:  E K Rofstad; N Zaffaroni; M E Hystad
Journal:  Int J Radiat Biol       Date:  1990-06       Impact factor: 2.694

View more
  1 in total

1.  Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.

Authors:  Diana Salvador; Verónica Bastos; Helena Oliveira
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.